BioMarin Pharmaceutical Inc.  

(Public, NASDAQ:BMRN)   Watch this stock  
Find more results for BMRN
120.28
-2.67 (-2.17%)
Apr 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 120.21 - 124.04
52 week 55.36 - 133.54
Open 122.38
Vol / Avg. 821,847.00/1.83M
Mkt cap 19.28B
P/E     -
Div/yield     -
EPS -0.92
Shares 159.14M
Beta 0.84
Inst. own 94%
Jun 9, 2015
Biomarin Pharmaceutical Inc Annual Shareholders Meeting - 12:00PM EDT - Add to calendar
May 6, 2015
Biomarin Pharmaceutical Inc at Deutsche Bank Health Care Conference - 10:40AM EDT - Add to calendar
Apr 30, 2015
Q1 2015 Biomarin Pharmaceutical Inc Earnings Call - 4:30PM EDT - Add to calendar
Apr 30, 2015
Q1 2015 Biomarin Pharmaceutical Inc Earnings Release - 4:00PM EDT - Add to calendar
Mar 3, 2015
Biomarin Pharmaceutical Inc at Cowen Health Care Conference
Feb 25, 2015
Q4 2014 Biomarin Pharmaceutical Inc Earnings Call - Webcast
Feb 25, 2015
Q4 2014 Biomarin Pharmaceutical Inc Earnings Release
Feb 23, 2015
Biomarin Pharmaceutical Inc at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day
Feb 12, 2015
Biomarin Pharmaceutical Inc at Leerink Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -30.23% -17.84%
Operating margin -25.45% -12.46%
EBITD margin - -11.37%
Return on average assets -11.36% -5.66%
Return on average equity -18.44% -9.34%
Employees 1,681 -
CDP Score - -

Address

105 Digital Dr
NOVATO, CA 94949-8703
United States - Map
+1-415-5066700 (Phone)
+1-415-3827889 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company�s product portfolio is comprised of four approved products and multiple investigational product candidates. Approved products include Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). It is conducting clinical trials on several product candidates for the treatment of various diseases. The Company is conducting preclinical development of several other enzyme product candidates for genetic and other metabolic diseases, including BMN-190 for the treatment of late infantile neuronal ceroid lipofuscinosis (LINCL), a form of Batten disease.

Officers and directors

Pierre Lapalme Director
Age: 73
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jean-Jacques Bienaime Chairman of the Board, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Daniel K. Spiegelman Chief Financial Officer, Executive Vice President
Age: 56
Bio & Compensation  - Reuters
Jeff Robert Ajer Executive Vice President, Chief Commercial Officer
Age: 52
Bio & Compensation  - Reuters
Robert A. Baffi Ph.D. Executive Vice President - Technical Operations
Age: 59
Bio & Compensation  - Reuters
Henry J. Fuchs M.D., Ph.D. Executive Vice President and Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
G. Eric Davis Senior Vice President, General Counsel, Secretary
Age: 43
Bio & Compensation  - Reuters
Richard J. Ranieri Senior Vice President - Human Resources and Corporate Affairs
Age: 60
Bio & Compensation  - Reuters
Brian R. Mueller Group Vice President, Corporate Controller
Age: 40
Bio & Compensation  - Reuters
Dennis J. Slamon M.D., Ph.D. Director
Age: 65
Bio & Compensation  - Reuters